Clinical Trial Update: A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients [NA]

View source ↗

Summary

A randomized trial is evaluating secukinumab versus tofacitinib for moderate-to-severe hidradenitis suppurativa in Chinese patients; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Cosentyx (secukinumab)
• XELJANZ (tofacitinib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Hidradenitis Suppurativa | NA | Status: RECRUITING